JAK1 and Eczematoid dermatitis: Both MTMZM and Pevisone can alleviate the symptoms of eczema, promote the recovery of skin lesions, reduce inflammation factors, and reduce the level of proteins associated with P38/NF-κB and JAK1/STAT6 pathways.